CorMatrix Cardiovascular has extended the application of its CorMatrix® ECM® having received U.S. FDA clearance to market the material for Vascular Repair.
CorMatrix® Cardiovascular, Inc. dedicates itself to developing and delivering innovative biomaterial devices that harness the body’s own innate ability to repair damaged cardiovascular tissues. The Company’s CorMatrix ECM® is constructed from a multi-laminate sheet of decellularized, non-crosslinked, lyophilized extracellular matrix (ECM) derived from porcine small intestinal submucosa (SIS). The material is evolving as the underpinning of a therapeutic platform for treating a variety of cardiovascular indications. It already had U.S. clearance and European CE mark approval for application as an implant for pericardial closure, cardiac tissue repair, as well as clearance for carotid repair.
Now with its newly extended clearance CorMatrix ECM for Vascular Repair is indicated for use as a patch material for repair and reconstruction of peripheral vasculature including the carotid, renal, iliac, femoral, and tibial blood vessels. It may be used for patch closure of vessels, as a pledget, or for suture line buttressing when repairing peripheral vessels.
According to Dr. Richard F. Neville, Professor of Surgery, Chief, Division of Vascular Surgery at George Washington University, “CorMatrix ECM for Vascular Repair is an innovative scaffold permitting the patient’s own stem cells to regenerate viable autogenous tissue improving the results of revascularization procedures that often fail due to myointimal hyperplasia and accelerated atherosclerosis.”
“The CorMatrix ECM for Vascular Repair is an expansion of the current indications for our CorMatrix ECM for Carotid Repair and was pursued due to requests by our physicians for a product that could be used to repair blood vessels throughout the vascular system. CorMatrix devices have now been used in over 100,000 patients worldwide to treat a growing number of cardiovascular indications. We are pleased that we can address these additional requests by physicians, providing a novel device to meet current clinical needs,” commented Andrew Green, CorMatrix Cardiovascular’s Executive Vice President of Operations. “Expansion of our current FDA-cleared devices to satisfy unmet indications further strengthens our leadership position in the field of ECM technologies and regenerative medicine, utilizing the patient’s own stem cells and their natural healing ability.”
Source: CorMatrix Cardiovascular, Inc., Business Wire